文献速递艾滋病与性传播感染

HIV感染成人短周期治疗:利匹韦林联合方案用药4天停药3天

Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

这项观察性研究纳入既往长期病毒学抑制且无耐药证据的HIV感染成人,将含利匹韦林的三药方案改为每周用药4天停药3天的短周期治疗并随访48周。第48周无病毒学失败,病毒学抑制率为30/30(100%),短周期治疗总体成功率为30/33(90.9%,95%CI=81.24%至100%),CD4+平均值增加+64个细胞/mm3(95%CI=-59至+187个细胞/mm3;P=0.052),未观察到不良事件,满意度问卷平均总分57.7/60(96.22%),71.3%的样本利匹韦林血浆浓度低于疗效阈值。作者认为含利匹韦林方案的短周期治疗可能成为特定既往长期病毒学抑制HIV感染者的有效替代选择。

要点

  • 第48周无病毒学失败,病毒学抑制率30/30(100%)。
  • 短周期治疗总体成功率30/33(90.9%,95%CI=81.24%至100%)。
  • 71.3%的样本利匹韦林血浆浓度低于疗效阈值。

核心结论

  • 含利匹韦林方案的短周期治疗可能成为特定既往长期病毒学抑制HIV感染者的有效替代选择。

研究设计与样本

  • 观察性研究,纳入既往长期病毒学抑制且无既往方案耐药证据、使用含利匹韦林三药方案的HIV感染成人。
  • 患者转为每周用药4天停药3天的短周期治疗,随访48周并定期检查。

主要发现

  • 第48周未观察到病毒学失败,病毒学抑制率为30/30(100%)。
  • 3例患者因其他原因转回持续治疗,短周期治疗总体成功率为30/33(90.9%,95%CI=81.24%至100%)。
  • CD4+平均值增加+64个细胞/mm3(95%CI=-59至+187个细胞/mm3;P=0.052)。
  • 未观察到不良事件,满意度问卷平均总分57.7/60(96.22%)。
  • 71.3%的样本利匹韦林血浆浓度低于疗效阈值。

关键数值与推荐

  • 病毒学抑制率30/30(100%)。
  • 短周期治疗总体成功率30/33(90.9%,95%CI=81.24%至100%)。
  • CD4+平均值变化+64个细胞/mm3(95%CI=-59至+187个细胞/mm3;P=0.052)。
  • 满意度问卷平均总分57.7/60(96.22%)。
  • 利匹韦林血浆浓度低于疗效阈值的样本占71.3%。

临床怎么用

  • 作者认为含利匹韦林方案的短周期治疗可能成为特定既往长期病毒学抑制HIV感染者的有效替代选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Short-cycle therapy (SCT) is the administration of ART for 4 or 5 consecutive days a week, followed by 3 or 2 days off therapy. Its benefits include improving patient satisfaction and reducing ART toxicity and costs. METHODS: In this observational study we included HIV-infected adults with a three-drug ART containing rilpivirine, a history of long-term virological suppression and no evidence of resistance to previous drug regimens. Patients switched to a SCT of 4 days on/3 days off and were followed for 48 weeks with regular check-ups. The primary outcome was virological suppression; secondary outcomes were changes in CD4+ cells and rilpivirine plasma concentration, the occurrence of adverse events and resistance in the case of failure, and patient satisfaction. RESULTS: At week 48 no virological failure was observed, with a virological suppression rate of 30/30 (100%). Three patients switched back to continuous therapy for other reasons, with an overall success rate of SCT of 30/33 (90.9%, 95% CI = 81.24% to 100%). The CD4+ mean value increased by +64 cells/mm3 (95% CI = -59 to +187 cells/mm3; P = 0.052). No adverse events were observed and the mean total score in the satisfaction questionnaire was 57.7/60 (96.22%). Rilpivirine plasma concentration was below the efficacy threshold in 71.3% of the samples, suggesting that the patients' characteristics, more than the drug's pharmacokinetics, played a role in maintaining virological suppression. CONCLUSIONS: SCT with rilpivirine-containing regimens could be an effective alternative to continuous therapy in selected HIV-infected patients with previous long-term virological suppression.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Luise D, Lattuada E, Rizzardo S, et al. Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy. J Antimicrob Chemother. 2022. PMID: 34849955. doi:10.1093/jac/dkab442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。